Cargando…

Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation

Mostrar otras versiones (1)

The use of the lipid lowering agent niacin is hampered by a frequent flush response which is largely mediated by prostaglandin (PG) D(2). Therefore, concomitant administration of the D-type prostanoid (DP) receptor antagonist laropiprant has been proposed to be a useful approach in preventing niacin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Philipose, Sonia, Konya, Viktoria, Lazarevic, Mirjana, Pasterk, Lisa M., Marsche, Gunther, Frank, Sasa, Peskar, Bernhard A., Heinemann, Akos, Schuligoi, Rufina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411562/ https://www.ncbi.nlm.nih.gov/pubmed/22870195 http://dx.doi.org/10.1371/journal.pone.0040222

Ejemplares similares

Laropiprant attenuates EP(3) and TP prostanoid receptor-mediated thrombus formation
por: Philipose, Sonia, et al.
Publicado: (2012)

E-type prostanoid receptor 4 (EP4) in disease and therapy
por: Konya, Viktoria, et al.
Publicado: (2013)

EP4 receptor stimulation down-regulates human eosinophil function
por: Luschnig-Schratl, Petra, et al.
Publicado: (2011)

The role of PGE(2) EP(4) receptors in the regulation of endothelial barrier function
por: Kampitsch, Nora, et al.
Publicado: (2012)

A biological target for antiplatelet therapy: the prostaglandin E(2) receptor EP(4)
por: Philipose, Sonia, et al.
Publicado: (2010)

Prostaglandin E(2 )acts via the EP(4 )receptor to inhibit platelet aggregation
por: Philipose, Sonia, et al.
Publicado: (2009)

Inhibitory effects of prostaglandin EP(4 )receptors on human eosinophils
por: Luschnig-Schratl, Petra, et al.
Publicado: (2009)

Oxidized plasma albumin promotes platelet-endothelial crosstalk and endothelial tissue factor expression
por: Pasterk, Lisa, et al.
Publicado: (2016)

Effects of PGH(2 )and PGD(2 )on CRTH2 and DP receptors in primary cells and co-expressed in HEK293 cells
por: Sedej, Miriam, et al.
Publicado: (2008)

The Role of PGE(2) in Alveolar Epithelial and Lung Microvascular Endothelial Crosstalk
por: Bärnthaler, Thomas, et al.
Publicado: (2017)

Aging affects high-density lipoprotein composition and function()
por: Holzer, Michael, et al.
Publicado: (2013)

Secretory phospholipase A(2) modified HDL rapidly and potently suppresses platelet activation
por: Curcic, Sanja, et al.
Publicado: (2017)

Activated prostaglandin D(2) receptors on macrophages enhance neutrophil recruitment into the lung
por: Jandl, Katharina, et al.
Publicado: (2016)

Abnormal composition and function of high‐density lipoproteins in atopic dermatitis patients
por: Trieb, Markus, et al.
Publicado: (2018)

The pulmonary microvascular endothelial barrier function is controlled by the PGE(2)-EP(4) signaling axis
por: Kónya, Viktória, et al.
Publicado: (2010)

EP4-mediated prostanoid signalling promotes oral cancer progression
por: Sapienza, Karen, et al.
Publicado: (2010)

Improved homology modeling of the human & rat EP(4) prostanoid receptors
por: Holt, Melissa C., et al.
Publicado: (2019)

Expression of the TPα and TPβ isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential
por: Mulvaney, Eamon P., et al.
Publicado: (2016)

Advanced oxidation protein products are antagonists of the HDL receptor SR-BI
por: Marsche, Gunther, et al.
Publicado: (2009)

The Gαs‐protein‐mediated pathway may be steadily stimulated by prostanoid EP2 receptors, but not by EP4 receptors
por: Fukushima, Keijo, et al.
Publicado: (2022)

Efficacy of Laropiprant in Minimizing Brain Injury Following Experimental Intracerebral Hemorrhage
por: Ahmad, Abdullah Shafique, et al.
Publicado: (2017)

Thromboxane prostanoid signaling in macrophages attenuates lymphedema and facilitates lymphangiogenesis in mice: TP signaling and lymphangiogenesis
por: Mishima, Toshiaki, et al.
Publicado: (2023)

Expression of Prostanoid EP3 Receptors in Oral Squamous Epithelium and Oral Squamous Cell Carcinoma
por: Kashif, Muhammad, et al.
Publicado: (2015)

Prostaglandin E(2) Prevents Hyperosmolar-Induced Human Mast Cell Activation through Prostanoid Receptors EP(2) and EP(4)
por: Torres-Atencio, Ivonne, et al.
Publicado: (2014)

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
por: Vosper, Helen
Publicado: (2011)

Differential effects of intragastric acid and capsaicin on gastric emptying and afferent input to the rat spinal cord and brainstem
por: Holzer, Peter, et al.
Publicado: (2005)

Detrimental role of the EP1 prostanoid receptor in blood-brain barrier damage following experimental ischemic stroke
por: Frankowski, Jan C., et al.
Publicado: (2015)

The affinity, intrinsic activity and selectivity of a structurally novel EP(2) receptor agonist at human prostanoid receptors
por: Coleman, R A, et al.
Publicado: (2019)

The D-type prostanoid (DP) receptor enhances the signaling of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)
por: Sedej, Miriam, et al.
Publicado: (2011)

Eicosapentaenoic acid (EPA)-induced inhibitory effects on porcine coronary and cerebral arteries involve inhibition of prostanoid TP receptors
por: Yoshioka, Kento, et al.
Publicado: (2022)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009)

Physiology and pathophysiology of prostanoid receptors
por: Narumiya, Shuh
Publicado: (2007)

Expression of prostaglandin E(2) prostanoid receptor EP2 and interleukin-1β in laryngeal carcinoma – preliminary study
por: Mochocki, Marcin, et al.
Publicado: (2015)

Prostanoids and Resolution of Inflammation – Beyond the Lipid-Mediator Class Switch
por: Schmid, Tobias, et al.
Publicado: (2021)

Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia
por: Kei, Anastazia, et al.
Publicado: (2014)

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia
por: Hu, Miao, et al.
Publicado: (2015)

Role of E-type prostaglandin receptor EP3 in the vasoconstrictor activity evoked by prostacyclin in thromboxane-prostanoid receptor deficient mice
por: Li, Zhenhua, et al.
Publicado: (2017)

Omidenepag, a Selective, Prostanoid EP2 Agonist, Does Not Suppress Adipogenesis in 3D Organoids of Human Orbital Fibroblasts
por: Hikage, Fumihito, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_79b3l1pjmetfmtuf9as7jrpr01